---
layout: post
title: "05/11/23"
category: neurocomic
tags: neurocomic
---

## Legal Psilocybin Mushrooms in Oregon: Prologue Citations

# [*Read the comic*](/assets/neuro_prologue.pdf)

# PAGE 1:
 
[The QR code leads to ORS 475A](https://oregonlegislature.gov/bills_laws/ors/ors475A.html)
	    
The final adopted rules can be found on the Oregon Secretary of State website,
under the [Oregon Health Authority Public Health Division Chapter 333, Division 333.](https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=7102)

# PAGE 2: 

More about M110 is at the [Oregon Health Authority’s Drug Addiction Treatment and 
Recovery Act web page](https://oregon.gov/oha/hsd/amh/pages/measure110.aspx)

# PAGE 3: 
     
The QR code leads to [Griffiths, Roland R et al. “Psilocybin produces
substantial and sustained decreases in depression and anxiety in
patients with life-threatening cancer: A randomized double-blind
trial.” *Journal of psychopharmacology (Oxford, England*) vol. 30,12
(2016): 1181-1197.](https://doi.org/10.1177/0269881116675513)
	     
*Further reading:*

[Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy 
on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 
2021;78(5):481–489.](https://doi.org/10.1001/jamapsychiatry.2020.3285)
          
[Oregon Psilocybin Advisory Board Rapid Evidence Review and Recommendations.](https://oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Oregon%20Psilocybin%20
Advisory%20Board%20Rapid%20Evidence%20Review.pdf)

# PAGE 4:

Bryan Roth, personal correspondence.
     
Roland Griffiths, from Michael Pollan’s How to Change Your Mind.
	     
Monnica Williams quote from [“Psychedelics and Race: A Profile of Dr. Monnica T. 
Williams”, written by Patricia Kubala in Society for Cultural Anthropology.](https://culanth.org/fieldsights/psychedelics-and-race-a-profile-of-dr-monnica-t-williams)

# PAGE 7: 

[Oregon Psilocybin Advisory Board Rapid Evidence Review and Recommendations, 
page 12 and page 27.](https://oregon.gov/oha/PH/PREVENTIONWELLNESS/Documents/Oregon%20Psilocybin%20
Advisory%20Board%20Rapid%20Evidence%20Review.pdf)

# PAGE 10: 

The trials by organizations currently furthest on the path towards FDA approval, 
[Usona’s PSIL201 trial for Major Depressive Disorder](https://clinicaltrials.gov/ct2/show/NCT03866174?term=PSIL201&draw=2&rank=2)
and [Compass Pathways’ COMP Single-Dose Psilocybin for a Treatment-Resistant Episode 
of Major Depression](https://nejm.org/doi/full/10.1056/NEJMoa2206443), both gave 25mg of
psilocybin to trial participants.

# PAGE 11:

Map of possible service center location from [Psychedelic Alpha’s
Oregon Psilocybin Services Act Local Jurisdiction Tracker.](https://psychedelicalpha.com/data/oregon-psilocybin-tracker)

# PAGE 13: 

The previously mentioned Usona and Compass Pathways trials have three and two integration sessions respectively.
